{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-23-000800","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.525940+00:00","generated_at":"2026-06-15T06:04:33.051769+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lexaria Bioscience prices public offering of 2.1M units at $0.95/unit for $2.0M gross proceeds","bullets":["2,106,000 units priced at $0.95 each, each unit comprising one share of common stock and one warrant.","Gross proceeds expected ~$2.0M before fees; warrants exercisable at $0.95 for 5 years.","Offering expected to close May 11, 2023; Maxim Group LLC sole placement agent.","Registration statement on Form S-1 (File No. 333-271096) declared effective May 8, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-23-000800","json":"https://secwatch.observer/filing/0001640334-23-000800.json","markdown":"https://secwatch.observer/filing/0001640334-23-000800.md","text":"https://secwatch.observer/filing/0001640334-23-000800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000800/0001640334-23-000800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000800/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:04:33.051769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b3586d4825b60faeed12c50cf49dd5702e332a34","claim":"Lexaria Bioscience Corp. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-05-08).","evidence_excerpt":"On May 8, 2023, Lexaria Bioscience Corp. (the “Company”) entered into a placement agency agreement dated as of May 8, 2023 (the “PAA”) with Maxim Group LLC (the “Placement Agent”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000800/0001640334-23-000800-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Maxim Group LLC"},{"label":"Effective","value":"2023-05-08"}],"fact_type":"material_agreement"},{"claim_id":"d9e58eb69b9d05071aa3a8b57c0a7342904858c7","claim":"Lexaria Bioscience Corp. entered into Security Purchase Agreement with certain institutional investors valued at up to an aggregate of $247,000 of Units (effective 2023-05-08).","evidence_excerpt":"On May 8, 2023, the Company also entered into a security purchase agreement (the “Purchase Agreement”) with certain institutional investors named therein (the “Purchasers”) in connection with the Offering.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000800/0001640334-23-000800-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors"},{"label":"Value","value":"up to an aggregate of $247,000 of Units"},{"label":"Effective","value":"2023-05-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}